Inhibitors that target the active conformation of FLT3 are type I inhibitors and are effective for AML patients with either FLT3-ITD or FLT3-TKD, while type II inhibitors target the inactive conformation of FLT3 and are effective only for AML patients with FLT3-ITD mutations. The gene discussed is FLT3; the disease is acute myeloid leukemia.